Research advisory trustee supporting the charity in the evaluation of academic research and biotech-stage R&D, advising on translation to therapeutic treatments for people with polycystic kidney disease. PKD affects about 1:500 people who currently have considerable unmet medical need from the disease and its complications.

Consulting to life sciences companies, financial services and pharma companies, with an accent on advising emerging life sciences companies on fundraising, an honest mirror reflecting how they may be viewed by investors, evaluation of business propositions, constructive and pro-active advice on strategic and tactical actions needed to achieve successful investor engagement and meetings, which may include introductions as well as investor-relations advice. Also: advising non-profit organisations and governmental organisations, especially around the early-stage innovation ecosystem and related financing environment for innovative companies.

Successfully delivering business development projects for the Centre of External Innovation including the Rare Diseases Unit and TAKcelerator ranging from Europe-wide scouting (biotech and academic), advisory and strategy, as well as initializing the Takeda European Innovation Event. Significantly improving on-strategy coverage in Europe.

Undertaking project and policy work related to investment in innovation, with an accent on corporate equity investment. Led on the ABPI's "The Rise of Corporate Venture Capital Investing" report. Initiated and co-manage the ABPI Corporate Venture Capital group to support the development of policies which can increase corporate equity investment in to the UK.

Providing unequaled coverage of UK and Irish academic institutes' spin-outs, reviewing and highlighting quality opportunities from Seed to Series B. LSP (Life Sciences Partners) is an independent European investment firm, providing financing for private and public life sciences companies. LSP’s mission is to connect investors to inventors, focusing on unmet medical needs. Since the late 1980s (first investment into Qiagen), the LSP team has invested in about 100 innovative enterprises, many of which have grown to become leaders of the global life sciences industry. With over €1.7 billion ($2.0 billion) of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is Europe’s leading life sciences investor. The LSP Health Economics Fund 2 invests in innovative products that can increase the quality of health care, while reducing the cost of care.

Led successful fundraising strategy over two financing rounds, key to Ducentis securing the LifeArc Seed Fund's first significant investment, which was covered in FT. Led outreach efforts to pharma business development and corporate venture, and participation in investment and partnering conferences, as part of the four person start-up team. Ducentis BioTherapeutics is an exciting pre-clinical stage biotech company developing first-in-class novel therapies for inflammation and autoimmune disease.

Akesios Associates provides financial strategy, representation and commercial development advice to Life Science companies. It offers strategic and financial solutions that enhance corporate, and where appropriate, shareholder value. Akesios draws on extensive capital markets, research and industry experience, incorporating product positioning, portfolio analysis, financial modelling, valuation, financing, M&A and representation/ communication.

Advisor for start-up fund investing in a portfolio of early stage programs related to regenerative medicine and life extension technologies, with a particular focus on strategy, mandate and deal flow.

Steering strategy, ratifying the Business Plan, policies and procedures, receiving reports on delivery.

Led and built OBN for a decade, transforming it from a University project into a diversified, financially sustainable association, building best-in-class activities including the largest life sciences investment conference in Europe, BioTrinity, the most cost-effective purchasing consortium for life sciences companies in the UK, and a wide range of networking events bringing together investors and senior executives. Established OBN as a powerful voice for emerging R&D companies and initiated then grew its advisory and consulting activities.Under my leadership OBN has:• Provided support to member companies raising financing, including catalysing multiple interactions with investors – 40% (£1.2bn) of the total raised by the life science sector was raised by OBN members over the 5 years to 2014• Highlighted the Biomedical Catalyst funding streams to its members who have between them been awarded £40m• Championed the UK life sciences sector, including helping secure the extension of the Biomedical Catalyst fund and the review of Entrepreneurs’ Relief• Successfully supported bids worth £40m to provide additional laboratory facilities• Grown its membership to 380 companies across the UK.I have led on strategy, corporate and business development, corporate client management, operationalizing strategy, horizon scanning, rebranding, diversification of income streams, strategic partnerships as well as managing the spin-out process from the University.

Active member of an the UK Trade and Investment "Biotechnology and Pharmaceutical Sector Advisory Group" (BPSAG) chaired by Kevin Cox, President of Avecia Biologics. UK Trade & Investment is the government organisation dedicated to helping UK businesses to export and grow overseas and encourage inward investment into the UK. BPSAG's role was to advise UK Trade and Investment Biotech & Pharma sector team on UK strengths, give strategic advice of priority markets and sub-sectors, advise Government on international trade and investment development opportunities, provide a knowledgable voice on policy development and the development of a UK Life Sciences strategy, develop an understanding of the competitive environment and benchmark the UK, ensuring representation of industry at a senior level in HM Government, including in meetings with Ministers.

Director of Oxford Informatics Ltd, a life science web portal specialist which included Bioinformatics.Net / MyBio. Advertising-supported income generation business model. In its peak was the world's largest curated bioinformatics web directory. Developed bespoke search engine for up to 1 million documents, and all round LAMP development on Linux with Apache using Perl & MySQL. Peak traffic to stable of niche web sites estimated to exceed 10,000 visits per day (2005). Content donated to Wikia under an Open Content Licence.

Lead project manager of regional development agency grant-funded network of UK bioinformatics companies.  Raised substantial private sponsorship funding and operating income against limited initial grant to extend scope of activity beyond original vision. Built a community through the delivery of focussed events in London and elsewhere including the BioConvergence partnering conference, Young Bioinformaticians Forum (entrepreneurship), BioSysBio (the precursor to the global synthetic biology conference SynBioBeta), as well as forums to discuss IP, Investment and business strategies around life sciences informatics, professional training and education. Conceptualization and delivery of Discovery Informatics Forum showcase and partnering conference in London, which was effectively the first bioinformatics conference hosting one-to-one meetings.